R

Regulus Therapeutics
D

RGLS

1.48000
USD
0.08
(5.71%)
Market Closed
Volume
5,625
EPS
-1
Div Yield
-
P/E
-1
Market Cap
96,940,198
OverviewSignalsIdeasNews
Related Instruments
    A
    ARWR
    -2.890
    (-13.49%)
    18.540 USD
    A
    AXSM
    -4.300
    (-4.41%)
    93.150 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    D
    DVAX
    -1.180
    (-8.81%)
    12.210 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    F
    FOLD
    -0.42300
    (-4.19%)
    9.68000 USD
    I
    IONS
    -2.970
    (-7.97%)
    34.290 USD
    S
    SRPT
    -4.470
    (-4.10%)
    104.600 USD
    V
    VKTX
    -3.960
    (-7.39%)
    49.620 USD
    X
    XLRN
    0
    (0%)
    0.000000 USD
    More
News

Title: Regulus Therapeutics

Sector: Healthcare
Industry: Biotechnology
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.